Literature DB >> 32580050

Chick embryo chorioallantoic membrane as a suitable in vivo model to evaluate drug delivery systems for cancer treatment: A review.

Francesca Damiani Victorelli1, Valéria Maria de Oliveira Cardoso2, Natália Noronha Ferreira3, Giovana Maria Fioramonti Calixto4, Carla Raquel Fontana5, Fátima Baltazar6, Maria Palmira Daflon Gremião7, Marlus Chorilli8.   

Abstract

Cancer represents a significant public health problem. More than 18.1 million people are annually diagnosed with cancer and 9.6 million die mainly due to metastatic disease. Chemotherapy has been one of the main cancer treatment modalities; however, most of the chemotherapeutic agents are non-specific, exhibiting several toxic side effects, which compromises the patient's quality of life. Therefore, it is necessary to search for new therapeutic alternatives, using for example, drug delivery systems (DDS) to target cancer cells, increasing the selectivity of chemotherapeutic drugs. This approach is promising; however, it is crucial to evaluate the biological performance of the systems. Although mammalian models continue to be explored for clinical applications, they are time-consuming and very restrictive from the ethical and legal perspectives. Hence, the chick embryo chorioallantoic membrane (CAM) has been shown to be a suitable in vivo model since it allows a more appropriate model for the study of drugs and/or DDS performance than in vitro tests. Thereby, this article revises the recent advances of DDS for cancer therapy, evaluating the feasibility of the CAM model.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Angiogenesis; Anti-angiogenic; CAM model; Cancer; Chicken embryos; Drug delivery systems

Mesh:

Substances:

Year:  2020        PMID: 32580050     DOI: 10.1016/j.ejpb.2020.06.010

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  6 in total

1.  Evaluation of curcumin-loaded polymeric nanocapsules with different coatings in chick embryo model: influence on angiogenesis, teratogenesis and oxidative stress.

Authors:  Felipe Barbosa de Carvalho; Marcelo Gomes de Gomes; Anne Suély Pinto Savall; Eduarda Monteiro Fidelis; Simone Pinton; Ana Claudia Funguetto Ribeiro; Félix Roman Munieweg; Carlos Alexandre Oelke; Sandra Elisa Haas
Journal:  Pharmacol Rep       Date:  2021-01-20       Impact factor: 3.024

2.  Proteomic Analysis of Chicken Chorioallantoic Membrane (CAM) during Embryonic Development Provides Functional Insight.

Authors:  Tamer A E Ahmed; Cristianne M M Cordeiro; Oluwadara Elebute; Maxwell T Hincke
Journal:  Biomed Res Int       Date:  2022-06-19       Impact factor: 3.246

Review 3.  Angiogenesis in the Avian Embryo Chorioallantoic Membrane: A Perspective on Research Trends and a Case Study on Toxicant Vascular Effects.

Authors:  Warren Burggren; Maria Rojas Antich
Journal:  J Cardiovasc Dev Dis       Date:  2020-12-05

Review 4.  3D In Vivo Models for Translational Research on Pancreatic Cancer: The Chorioallantoic Membrane (CAM) Model.

Authors:  Eric Pion; Julia Karnosky; Sofie Boscheck; Benedikt J Wagner; Katharina M Schmidt; Stefan M Brunner; Hans J Schlitt; Thiha Aung; Christina Hackl; Silke Haerteis
Journal:  Cancers (Basel)       Date:  2022-07-31       Impact factor: 6.575

5.  A 3D In Vivo Model for Studying Human Renal Cystic Tissue and Mouse Kidney Slices.

Authors:  Eva-Marie Bichlmayer; Lina Mahl; Leo Hesse; Eric Pion; Victoria Haller; Andreas Moehwald; Christina Hackl; Jens M Werner; Hans J Schlitt; Siegfried Schwarz; Philipp Kainz; Christoph Brochhausen; Christian Groeger; Felix Steger; Oliver Kölbl; Christoph Daniel; Kerstin Amann; Andre Kraus; Björn Buchholz; Thiha Aung; Silke Haerteis
Journal:  Cells       Date:  2022-07-22       Impact factor: 7.666

6.  DJ-1/FGFR-1 Signaling Pathway Contributes to Sorafenib Resistance in Hepatocellular Carcinoma.

Authors:  Xin Chen; Guohua Yang; Xiaohong Guo; Jing Zhang; Wei Sun; Dongbo Liu; Hui Wang; Shunfang Liu
Journal:  Oxid Med Cell Longev       Date:  2022-06-20       Impact factor: 7.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.